Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: An analytical review

Clinical Infectious Diseases

Volumn 37, Issue 1, 2003, Pages 101-112

  Korenromp, Eline L ^a   Scano, Fabio ^a   Williams, Brian G ^a   Dye, Christopher ^a   Nunn, Paul ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN;

ADOLESCENT; CONTROLLED STUDY; DRUG EFFICACY; ENDEMIC DISEASE; FOLLOW UP; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MORBIDITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; INCIDENCE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RECURRENCE; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 0037559362     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375220     Document Type: Review

References (76)

1. Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-93.
2. Maher D, Chaulet P, Spinaci S, et al. Treatment of tuberculosis: guidelines for national programmes. WHO/TB/97.220. Geneva: World Health Organization, 1997.
3. Gomez Marin JE, Rigouts L, Villegas Londono LE, et al. Restriction fragment length polymorphism (RFLP) analysis and tuberculosis epidemiology. Bull Pan Am Health Organ 1995; 29:226-36.
4. Fine PEM, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med 1999; 341:1226-7.
5. Harries AD, Hargreaves NJ, Salaniponi FM. Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa. Int J Tuberc Lung Dis 2001; 5:1109-15.
6. Vynnycky E, Fine PEM. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119:183-201.
7. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
8. Wilkinson D. Drugs for preventing tuberculosis in HIV infected persons. Cochrane Database Syst Rev 2000:CD000171.
9. Godfrey-Faussett P, Githui W, Batchelor B, et al. Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tuber Lung Dis 1994; 75:199-202.
10. Gilks CF, Godfrey-Faussett P, Batchelor BIF, et al. Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. AIDS 1997; 11:911-8.
11. Van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341:1174-9.
12. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112:407-15.
13. Kelly PM, Cumming RG, Kaldor JM. HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Trans R Soc Trop Med Hyg 1999; 93:287-93.
14. Banda H, Kang'ombe C, Harries AD, et al. Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment. Int J Tuberc Lung Dis 2000; 4:968-74.
15. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Int Med 2003; 163:1009-21.
16. World Health Organization. Global tuberculosis control: WHO report 2001. Document WHO/CDS/TB/2001.287. Geneva: World Health Organization, 2001.
17. Mallory KF, Churchyard GJ, Kleinschmidt I, et al. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4:455-62.
18. Connolly C, Reid A, Davies G, et al. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999; 13:1543-7.
19. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study. Am Rev Respir Dis 1976; 114:471-5.
20. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. East-African/British Medical Research Councils. Am Rev Respir Dis 1977; 116:3-8.
21. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: second report. Third East African/British Medical Research Council Study. Tubercle 1980; 61:59-69.
22. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 1986; 67:5-15.
23. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22:827-33.
24. Hawken M, Nunn P, Gathua P, et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet 1993; 342:332-7.
25. Johnson JL, Okwera A, Vjecha MJ, et al. Risk factors for relapse in HIV-1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1:446-53.
26. Johnson JL, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 2000;4:1032-40.
27. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1 and HIV-2 associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9:1185-91.
28. Perriens JH, St Louis ME, Mukadi YD, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. N Engl J Med 1995; 332:779-84.
29. Malkin JE, Prazuck T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis 1997; 1:68-74.
30. Chaulet P, Boulahbal F. Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis [in French]. Groupe de Travail sur la Chimiotherapie de la Tuberculose. Tuber Lung Dis 1995; 76:407-12.
31. Gonzalez Montaner LJ, Leston JM, Cetrangolo A, et al. Simplified short-course treatment of pulmonary tuberculosis: experience with a regimen of ethambutol, rifampicin and isoniazid for 2 months followed by isoniazid or rifampicin for 4 months. Bull Int Union Tuberc 1976; 51:87-9.
32. Lourenco MC, Grinsztejn B, Fandinho-Montes FC, et al. Genotypic patterns of multiple isolates of M. tuberculosis from tuberculous HIV patients. Trop Med Int Health 2000; 5:488-94.
33. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000; 160:630-6.
34. Chaisson RE, Clermont HC, Holt AE, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154:1034-8.
35. Fitzgerald DW, Desvarieux M, Severe P, et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1 infected individuals: a randomised trial. Lancet 2000; 356:1470-4.
36. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability: the report of final results. Ann Intern Med 1990; 112:397-406.
37. Theuer CP, Hopewell PC, Elias D, et al. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990; 162:8-12.
38. Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150:1499-502.
39. Driver CR, Munsiff SS, Kundamal N, et al. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with HIV in New York City. Clin Infect Dis 2001; 33:1762-9.
40. el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26:1148-58.
41. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353:1843-7.
42. Das S, Chan SL, Allen BW, et al. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis 1993; 74:47-51.
43. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong: the results up to 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Resp Dis 1977; 115:727-35.
44. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1987; 136:1339-42.
45. Chan SL, Wong PC, Tam CM. 4-, 5- And 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong. Tuber Lung Dis 1994; 75:245-50.
46. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 1991; 143:700-6.
47. Tam CM, Chan SL, Kam KM, et al. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis 2000; 4:262-7.
48. Punnotok J, Pumprueg U, Chakorn T. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. J Med Assoc Thai 1995; 78:298-304.
49. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1986; 133:779-83.
50. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1988; 137:1147-50.
51. Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3:126-32.
52. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/ British Medical Research Council. Am Rev Respir Dis 1991; 143:707-12.
53. Baba H, Shinkai A, Izhunchi R, et al. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Bull Int Union Tuberc 1984; 59:26-30.
54. Santha T, Nazareth O, Krishnamurthy MS, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in south India - 5-year follow up. Tubercle 1989; 70:229-34.
55. Balasubramanian R, Sivasubramanian S, Vijayan VK, et al. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle 1990; 71:253-8.
56. Das S, Paramasivan CN, Lowrie DB, et al. S6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Tuber Lung Dis 1995; 76:550-4.
57. Sahadevan R, Narayanan S, Paramasivan CN, et al. Restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, India, by use of direct-repeat probe. J Clin Microbiol 1995; 33:3037-9.
58. Bandera A, Gori A, Catozzi L, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001; 39:2213-8.
59. The British Thoracic & Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis: a controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; 2:1102-4.
60. de Boer AS, van Soolingen D. Recurrent tuberculosis due to exogenous reinfection [letter]. N Engl J Med 2000; 342:1050-1.
61. Roussel G, Bernadou M, Cheminat JC, et al. Long-term results of a trial of short-term chemotherapy: French study 6.9.12 [in French]. Rev Fr Mal Respir 1983; 11:847-57.
62. Pretet S. Short-term chemotherapy of tuberculosis: cooperative French trial [in French]. Rev Fr Mal Respir 1983; 11:859-66.
63. Perronne C, Ghoubontni A, Leport C, et al. Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV? Tuber Lung Dis 1992; 73:39-44.
64. Lemaitre N, Sougakoff W, Truffot C, et al. Analysis of restriction fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients with several episodes of tuberculosis [in French]. Pathol Biol (Paris) 1996; 44:452-5.
65. Soriano E, Mallolas J, Gatell JM, et al. Characteristics of tuberculosis in HIV-infected patients: a case-control study. AIDS 1988; 2:429-32.
66. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163:717-20.
67. Strassle A, Putnik J, Weber R, et al. Molecular epidemiology of Mycobacterium tuberculosis strains isolated from patients in a human immunodeficiency virus cohort in Switzerland. J Clin Microbiol 1997; 35:374-8.
68. Sudre P, Pfyffer GE, Bodmer T, et al. Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: a countrywide 9-year cohort study. Swiss HIV Cohort Study. Infection 1999; 27:323-30.
69. Zierski M, Bek E, Long MW, et al. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. Am Rev Respir Dis 1981; 124:249-51.
70. Snider DEJ, Rogowski J, Zierski M, et al. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am Rev Respir Dis 1982; 125:265-7.
71. Snider DE Jr, Zierski M, Graczyk J, et al. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade. Eur J Respir Dis 1986; 68:12-8.
72. Snider DE, Graczyk J, Bek E, et al. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130:1091-4.
73. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev 2000:CD001362.
74. Harries AD, Maher D, Nunn P. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa. Bull World Health Organ 1998; 76:651-62.
75. Harries AD, Hargreaves NJ, Kwanjana JH, et al. Relapse and recurrent tuberculosis in the context of a National Tuberculosis Control Programme. Trans R Soc Trop Med Hyg 2000; 94:247-9.
76. Fitzpatrick LK, Okwera A, Mugerwa R, et al. An investigation of suspected exogenous reinfection n tuberculosis patients in Kampala, Uganda. Int J Tuberc Lung Dis 2002; 6:550-2.